X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
4.410
+0.450 (11.36%)
At close: Jul 10, 2026, 4:00 PM EDT
4.300
-0.110 (-2.49%)
After-hours: Jul 10, 2026, 4:20 PM EDT
X4 Pharmaceuticals Revenue
X4 Pharmaceuticals had revenue of $2.71M in the quarter ending March 31, 2026, a decrease of -90.60%. This brings the company's revenue in the last twelve months to $9.01M, down -71.26% year-over-year. In the year 2025, X4 Pharmaceuticals had annual revenue of $35.11M with 1,273.21% growth.
Revenue (ttm)
$9.01M
Revenue Growth
-71.26%
P/S Ratio
44.78
Revenue / Employee
$200,311
Employees
45
Market Cap
415.95M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 35.11M | 32.56M | 1,273.21% |
| Dec 31, 2024 | 2.56M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 227.18M |
| Vanda Pharmaceuticals | 217.78M |
| Fennec Pharmaceuticals | 51.00M |
| Foghorn Therapeutics | 28.22M |
| Fate Therapeutics | 6.32M |
| Lyell Immunopharma | 31.00K |
| Inhibikase Therapeutics | 1.00 |
XFOR News
- 10 hours ago - X4 Pharmaceuticals initiated with an Overweight at Wells Fargo - TheFly
- 3 days ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 9 days ago - X4 Pharmaceuticals appoints CAMP4 Therapeutics CFO Kelly Gold to board - TheFly
- 9 days ago - X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors - GlobeNewsWire
- 5 weeks ago - X4 Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 5 weeks ago - X4 Pharmaceuticals initiated with an Outperform at Leerink - TheFly
- 5 weeks ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference - GlobeNewsWire